Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Madrigal Pharmaceuticals (MDGL) over the last 12 years, with Dec 2024 value amounting to $100.0 million.

  • Madrigal Pharmaceuticals' Cash & Equivalents rose 27.08% to $295.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $295.7 million, marking a year-over-year increase of 27.08%. This contributed to the annual value of $100.0 million for FY2024, which is 0.10% up from last year.
  • As of FY2024, Madrigal Pharmaceuticals' Cash & Equivalents stood at $100.0 million, which was up 0.10% from $99.9 million recorded in FY2023.
  • In the past 5 years, Madrigal Pharmaceuticals' Cash & Equivalents registered a high of $331.5 million during FY2022, and its lowest value of $36.3 million during FY2021.
  • Over the past 3 years, Madrigal Pharmaceuticals' median Cash & Equivalents value was $100.0 million (recorded in 2024), while the average stood at $177.2 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 814.14% in 2022, then crashed by 69.86% in 2023.
  • Yearly analysis of 5 years shows Madrigal Pharmaceuticals' Cash & Equivalents stood at $54.0 million in 2020, then plummeted by 32.84% to $36.3 million in 2021, then soared by 814.14% to $331.5 million in 2022, then slumped by 69.86% to $99.9 million in 2023, then climbed by 0.10% to $100.0 million in 2024.